## Michael Hershfield

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8899499/publications.pdf

Version: 2024-02-01

		430874	454955
32	1,100	18	30
papers	citations	h-index	g-index
2.2	2.2	2.2	10.47
33	33	33	1247
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC. Blood, 2022, 140, 685-705.	1.4	26
2	Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency. Blood, 2021, 138, 1304-1316.	1.4	28
3	Normal IgH Repertoire Diversity in an Infant with ADA Deficiency After Gene Therapy. Journal of Clinical Immunology, 2021, 41, 1597-1606.	3.8	О
4	Deficiency of Adenosine Deaminase 2—a Monogenic Cause of Wunderlich Syndrome. Journal of Clinical Immunology, 2021, 41, 1693-1695.	3.8	0
5	Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients. Journal of Clinical Immunology, 2021, 41, 1633-1647.	3.8	43
6	Intrinsic Defects in B Cell Development and Differentiation, T Cell Exhaustion and Altered Unconventional T Cell Generation Characterize Human Adenosine Deaminase Type 2 Deficiency. Journal of Clinical Immunology, 2021, 41, 1915-1935.	3.8	23
7	Deficiency of adenosine deaminase 2: a case series revealing clinical manifestations, genotypes and treatment outcomes from Turkey. Rheumatology, 2020, 59, 254-256.	1.9	4
8	A Case with Purine Nucleoside Phosphorylase Deficiency Suffering from Late-Onset Systemic Lupus Erythematosus and Lymphoma. Journal of Clinical Immunology, 2020, 40, 833-839.	3.8	16
9	Deficiency of Adenosine Deaminase 2 (DADA2): Hidden Variants, Reduced Penetrance, and Unusual Inheritance. Journal of Clinical Immunology, 2020, 40, 917-926.	3.8	32
10	Clinical, Immunological, and Molecular Features of Severe Combined Immune Deficiency: A Multi-Institutional Experience From India. Frontiers in Immunology, 2020, 11, 619146.	4.8	31
11	Human adenosine deaminase 2 deficiency: A multiâ€faceted inborn error of immunity. Immunological Reviews, 2019, 287, 62-72.	6.0	54
12	Childhood Hodgkin Lymphoma: Think DADA2. Journal of Clinical Immunology, 2019, 39, 26-29.	3.8	20
13	ADA2 deficiency: Clonal lymphoproliferation in a subset of patients. Journal of Allergy and Clinical Immunology, 2018, 141, 1534-1537.e8.	2.9	71
14	Complexities of genetic diagnosis illustrated by an atypical case of congenital hypoplastic anemia. Journal of Physical Education and Sports Management, 2018, 4, a003384.	1.2	12
15	Renal Amyloidosis in Deficiency of Adenosine Deaminase 2: Successful Experience With Canakinumab. Pediatrics, 2018, 142, .	2.1	23
16	ADA Deficiency: Evaluation of the Clinical and Laboratory Features and the Outcome. Journal of Clinical Immunology, 2018, 38, 484-493.	3.8	26
17	ADA2 Deficiency Mimicking Idiopathic Multicentric Castleman Disease. Pediatrics, 2018, 142, .	2.1	26
18	Deficiency of Adenosine Deaminase 2 (DADA2) Presenting As Familial Hodgkin Lymphoma. Blood, 2018, 132, 5373-5373.	1.4	1

MICHAEL HERSHFIELD

#	Article	IF	CITATIONS
19	Screening of 181 Patients With Antibody Deficiency for Deficiency of Adenosine Deaminase 2 Sheds New Light on the Disease in Adulthood. Arthritis and Rheumatology, 2017, 69, 1689-1700.	5.6	103
20	Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2. Blood, 2017, 130, 2682-2688.	1.4	140
21	Autoimmune phenotype with type I interferon signature in two brothers with ADA2 deficiency carrying a novel CECR1 mutation. Pediatric Rheumatology, 2017, 15, 67.	2.1	58
22	Diamond-Blackfan Anemia Phenotype Caused By Deficiency of Adenosine Deaminase 2. Blood, 2017, 130, 874-874.	1.4	4
23	Combined immunodeficiencies: twenty years experience from a single center in Turkey. Central-European Journal of Immunology, 2016, 1, 107-115.	1.2	20
24	Novel compound heterozygous variants in <i>CECR1</i> gene associated with childhood onset polyarteritis nodosa and deficiency of ADA2. Rheumatology, 2016, 55, 1145-1147.	1.9	22
25	Two patients with novel missense mutation in the purine nucleoside phosphorylase gene without serious or recurrent infections. Clinical and Experimental Neuroimmunology, 2016, 7, 79-82.	1.0	3
26	Deficiency of Adenosine Deaminase 2 Causes Antibody Deficiency. Journal of Clinical Immunology, 2016, 36, 179-186.	3.8	78
27	Adenosine Deaminase-Deficient Severe Combined Immunodeficiency and Diffuse Large B-Cell Lymphoma. Pediatric, Allergy, Immunology, and Pulmonology, 2015, 28, 138-142.	0.8	4
28	Adenosine Deaminase 2 Deficiency As a Cause of Pure Red Cell Aplasia Mimicking Diamond Blackfan Anemia. Blood, 2015, 126, 3615-3615.	1.4	9
29	Diagnosis of immunodeficiency caused by a purine nucleoside phosphorylase defect by using tandem mass spectrometry on dried blood spots. Journal of Allergy and Clinical Immunology, 2014, 134, 155-159.e3.	2.9	56
30	Tandem mass spectrometry, but not T-cell receptor excision circle analysis, identifies newborns with late-onset adenosine deaminase deficiency. Journal of Allergy and Clinical Immunology, 2013, 131, 1604-1610.	2.9	65
31	Comparative Results of Gene Therapy for Adenosine Deaminase Deficiency with or without PEG-ADA Withdrawal and Myelosuppressive Chemotherapy Blood, 2007, 110, 501-501.	1.4	2
32	Mitochondrial Basis for Immune Deficiency. Journal of Experimental Medicine, 2000, 191, 2197-2208.	8.5	100